Phase II North Central Cancer Treatment Group study of 2- chlorodeoxyadenosine in patients with recurrent glioma

S. Vincent Rajkumar, Patrick A. Burch, Suresh Nair, Robert P. Dinapoli, Bernd Scheithauer, Judith R. O'Fallon, Paul S. Etzell, John M. Leitch, Roscoe F. Morton, Randolph S. Marks

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

There is no standard treatment for patients with recurrent gliomas, and their prognosis remains poor. 2-Chlorodeoxyadenosine is a purine analogue that has significant activity in many low-grade lymphoproliferative disorders. The authors conducted a phase II study to determine the efficacy of 2-chlorodeoxyadenosine in patients with recurrent gliomas. Patients with a histologically confirmed primary brain tumor with evidence of progression after radiation therapy were eligible. Protocol treatment consisted of 2- chlorodeoxyadenosine 7.0 mg/m2 intravenously on days 1 through 5 every 28 days. For those with a history of prior nitrosourea therapy, the dose of 2- chlorodeoxyadenosine was reduced to 5.6 mg/m2 on days 1 through 5. Treatment was continued until progression or a maximum of 12 cycles. Fifteen patients with recurrent astrocytomas or oligoastrocytomas of all grades were entered in the study. Treatment was well tolerated. Major toxicities were myelosuppression and neurotoxicity. No responses were seen. The authors conclude that although 2-chlorodeoxyadenosine is well tolerated, no demonstrable activity in patients with recurrent gliomas was established.

Original languageEnglish (US)
Pages (from-to)168-171
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume22
Issue number2
DOIs
StatePublished - Apr 1999

Keywords

  • 2-Chlorodeoxyadenosine
  • Brain tumors
  • Chemotherapy
  • Clinical trial
  • Recurrent gliomas

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II North Central Cancer Treatment Group study of 2- chlorodeoxyadenosine in patients with recurrent glioma'. Together they form a unique fingerprint.

Cite this